We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Fibrocell Science, Inc. (“Fibrocell” or the “Company”) (NASDAQGS: FCSC) to Castle Creek Pharmaceutical Holdings, Inc. (“CCP Holdings”). Under the terms of the deal, Castle Creek Pharmaceutical Holdings will purchase all outstanding shares of Fibrocell common stock for $3.00 per share.
The Fibrocell merger investigation concerns whether the Board of Fibrocell breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether CCP Holdings is underpaying for Fibrocell shares, thus unlawfully harming Fibrocell shareholders.
To receive more information, please fill out the form.